These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10781514)

  • 1. A controlled study of vigabatrin and visual abnormalities.
    Manuchehri K; Goodman S; Siviter L; Nightingale S
    Br J Ophthalmol; 2000 May; 84(5):499-505. PubMed ID: 10781514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vigabatrin and visual field defects in pediatric epilepsy patients.
    You SJ; Ahn H; Ko TS
    J Korean Med Sci; 2006 Aug; 21(4):728-32. PubMed ID: 16891821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual field defects in patients taking vigabatrin.
    Midelfart A; Midelfart E; Brodtkorb E
    Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
    Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
    Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual field defects associated with vigabatrin therapy.
    Lawden MC; Eke T; Degg C; Harding GF; Wild JM
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
    Fledelius HC
    Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigabatrin visual toxicity: evolution and dose dependence.
    Malmgren K; Ben-Menachem E; Frisén L
    Epilepsia; 2001 May; 42(5):609-15. PubMed ID: 11380567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
    Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
    Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vigabatrin-induced visual dysfunction in Chinese patients with refractory epilepsy.
    Hui AC; Liu DT; Wong KK; Man BL; Leung T; Lam PT; Lam DS
    Eur J Ophthalmol; 2008; 18(4):624-7. PubMed ID: 18609486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
    Ponjavic V; Andréasson S
    Doc Ophthalmol; 2001 Jan; 102(1):63-72. PubMed ID: 11475366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
    Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
    Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual field and electrophysiological abnormalities due to vigabatrin.
    van der Torren K; Graniewski-Wijnands HS; Polak BC
    Doc Ophthalmol; 2002 Mar; 104(2):181-8. PubMed ID: 11999625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
    Nousiainen I; Kälviäinen R; Mäntyjärvi M
    Ophthalmology; 2000 May; 107(5):884-8. PubMed ID: 10811079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
    Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
    Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
    Sorri I
    Acta Ophthalmol Scand; 2002 Jun; 80(3):343-4. PubMed ID: 12059879
    [No Abstract]   [Full Text] [Related]  

  • 20. Visual field defects in pediatric patients on vigabatrin monotherapy.
    Ascaso FJ; Lopez MJ; Mauri JA; Cristobal JA
    Doc Ophthalmol; 2003 Sep; 107(2):127-30. PubMed ID: 14661902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.